FDA denies Unicycive's NDA for Oxylanthanum Carbonate due to vendor issues; company eyes quick resolution with alternate ...

Unicycive Therapeutics has hit a bump on the road in its mission to bring its hyperphosphatemia treatment candidate to ...

By adopting FDA-endorsed endpoints that are easier to achieve, Dimerix has bolstered the chances of its pivotal kidney drug trial succeeding.

In a first step toward FDA approval of kidney xenotransplantation, a living human with end-stage kidney disease may receive a ...

FDA issues a complete response letter for oxylanthanum carbonate, a treatment for hyperphosphatemia in patients with chronic ...

The 61-year-old man received a new kidney from a deceased donor after being diagnosed with “nephrosclerosis-related end-stage ...

Using CRISPR to correct the mutations behind polycystic kidney disease could counter some of the damage the condition causes ...

Unicycive, which was seeking approval of oxylanthanum carbonate to treat hyperphosphatemia in patients with chronic kidney disease on dialysis, said the FDA issued a so-called complete response letter ...

Altimmune shares cratered more than 50% on Thursday after its experimental obesity drug did not significantly improve liver ...

Adults with type 2 diabetes and chronic kidney disease have a lower risk for adverse renal outcomes with semaglutide, ...

June 30, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. ("Unicycive” or the "Company”) (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney ...

With its demonstrated clinical benefits and superior selectivity profile, SC0062 is positioned to potentially become a ...